Top 6 Mutual Funds with RVMD.W / Revolution Medicines, Inc. - Equity Warrant (NasdaqGS)

Revolution Medicines, Inc. - Equity Warrant
THIS SYMBOL IS NO LONGER ACTIVE

Top 6 Mutual Funds with RVMD.W / Revolution Medicines, Inc. - Equity Warrant

This page shows all mutual funds that have reported positions in RVMD.W / Revolution Medicines, Inc. - Equity Warrant. Green rows indicate new positions. Click the link icon to see the full transaction history.

Upgrade to unlock premium data and export to Excel .

File Date Source Investor Type Avg Price
(Est)		 Shares Δ Shares
(%)		 Reported
Value
($1000)		 Δ Value
(%)		 Port Alloc
(%)
2025-08-25 NP MMBUX - MassMutual Select T. Rowe Price Small and Mid Cap Blend Fund Class I 1,166 0.00 0
2025-07-22 NP DMSFX - Destinations Multi Strategy Alternatives Fund Class I 88,320 0.00 9 28.57
2025-08-26 NP PRHSX - T. Rowe Price Health Sciences Fund, Inc. This fund is a listed as child fund of Price T Rowe Associates Inc /md/ and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 198,505 0.00 54 657.14
2025-08-26 NP PRNHX - T. Rowe Price New Horizons Fund, Inc. This fund is a listed as child fund of Price T Rowe Associates Inc /md/ and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 302,672 0.00 82 636.36
2025-06-25 NP TMSRX - T. Rowe Price Multi-Strategy Total Return Fund This fund is a listed as child fund of Price T Rowe Associates Inc /md/ and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 2,200 0.00 0
2025-08-29 NP JAFMX - Health Sciences Trust NAV 4,502 0.00 1
Other Listings
US:RVMDW $0.20
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista

© 2015-2025 Fintel Ventures LLC. All rights reserved. Fintel® is a registered trademark.

This website is provided “as is” without any representations or warranties, express or implied. Fintel makes no representations or warranties in relation to this website or the information and materials provided on this website. Nothing on this website constitutes, or is meant to constitute, advice of any kind. If you require advice in relation to any financial matter you should consult an appropriate professional.

About Fintel
Top Investors
Features
Explore
Help Center